IN2014DN07410A - - Google Patents
Info
- Publication number
- IN2014DN07410A IN2014DN07410A IN7410DEN2014A IN2014DN07410A IN 2014DN07410 A IN2014DN07410 A IN 2014DN07410A IN 7410DEN2014 A IN7410DEN2014 A IN 7410DEN2014A IN 2014DN07410 A IN2014DN07410 A IN 2014DN07410A
- Authority
- IN
- India
- Prior art keywords
- pharmaceutically acceptable
- inhibitor
- prodrug
- relates
- pharmaceutical combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261619502P | 2012-04-03 | 2012-04-03 | |
| PCT/US2013/034759 WO2013151913A1 (en) | 2012-04-03 | 2013-04-01 | Tyrosine kinase inhibitor combinations and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN07410A true IN2014DN07410A (ru) | 2015-04-24 |
Family
ID=48184451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN7410DEN2014 IN2014DN07410A (ru) | 2012-04-03 | 2013-04-01 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150051210A1 (ru) |
| EP (1) | EP2833917A1 (ru) |
| JP (1) | JP2015512447A (ru) |
| KR (1) | KR20140146086A (ru) |
| CN (1) | CN104244982A (ru) |
| AU (1) | AU2013243737B2 (ru) |
| CA (1) | CA2866321A1 (ru) |
| IN (1) | IN2014DN07410A (ru) |
| MX (1) | MX2014011987A (ru) |
| RU (1) | RU2014143213A (ru) |
| WO (1) | WO2013151913A1 (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015144804A1 (en) | 2014-03-26 | 2015-10-01 | Astex Therapeutics Ltd | Combinations |
| CA2954862A1 (en) * | 2014-07-31 | 2016-02-04 | Novartis Ag | Combination therapy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| DE102005038537A1 (de) | 2005-08-16 | 2007-02-22 | Merck Patent Gmbh | 1-Acyldihydropyrazolderivate |
| US8030305B2 (en) | 2005-12-21 | 2011-10-04 | Janssen Pharmaceutica N.V. | Triazolopyridazines as kinase modulators |
| NL2000613C2 (nl) | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| JP5378222B2 (ja) | 2006-10-23 | 2013-12-25 | エスジーエックス ファーマシューティカルズ、インコーポレイテッド | タンパク質キナーゼ調節物質としての二環式トリアゾール |
| HUE026659T2 (en) * | 2006-11-22 | 2016-07-28 | Incyte Holdings Corp | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| JP4994044B2 (ja) * | 2007-01-05 | 2012-08-08 | シェブロンジャパン株式会社 | 潤滑油組成物 |
| JP5926487B2 (ja) * | 2007-04-13 | 2016-05-25 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ＥｒｂＢ療法に耐性である癌を治療するための方法 |
| CN102016592A (zh) * | 2008-04-29 | 2011-04-13 | 诺瓦提斯公司 | 监测成纤维细胞生长因子受体的激酶活性的调节的方法及所述方法的应用 |
| EP2288383A1 (en) * | 2008-05-14 | 2011-03-02 | Amgen, Inc | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
| AU2010283806A1 (en) * | 2009-08-12 | 2012-03-01 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
| JP2013537918A (ja) * | 2010-09-27 | 2013-10-07 | エクセリクシス， インク． | 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬 |
-
2013
- 2013-04-01 US US14/388,251 patent/US20150051210A1/en not_active Abandoned
- 2013-04-01 CN CN201380018928.6A patent/CN104244982A/zh active Pending
- 2013-04-01 WO PCT/US2013/034759 patent/WO2013151913A1/en active Application Filing
- 2013-04-01 MX MX2014011987A patent/MX2014011987A/es unknown
- 2013-04-01 AU AU2013243737A patent/AU2013243737B2/en not_active Ceased
- 2013-04-01 IN IN7410DEN2014 patent/IN2014DN07410A/en unknown
- 2013-04-01 EP EP13718671.4A patent/EP2833917A1/en not_active Withdrawn
- 2013-04-01 CA CA2866321A patent/CA2866321A1/en not_active Abandoned
- 2013-04-01 KR KR1020147027542A patent/KR20140146086A/ko not_active Application Discontinuation
- 2013-04-01 JP JP2015504647A patent/JP2015512447A/ja active Pending
- 2013-04-01 RU RU2014143213A patent/RU2014143213A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2833917A1 (en) | 2015-02-11 |
| CN104244982A (zh) | 2014-12-24 |
| MX2014011987A (es) | 2014-11-10 |
| WO2013151913A1 (en) | 2013-10-10 |
| KR20140146086A (ko) | 2014-12-24 |
| US20150051210A1 (en) | 2015-02-19 |
| AU2013243737B2 (en) | 2016-06-30 |
| RU2014143213A (ru) | 2016-05-27 |
| JP2015512447A (ja) | 2015-04-27 |
| AU2013243737A1 (en) | 2014-09-25 |
| CA2866321A1 (en) | 2013-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN00598A (ru) | ||
| MX361499B (es) | Baricitinib deuterado. | |
| PH12014501653A1 (en) | Metalloenzyme inhibitor compounds | |
| EP2931730A4 (en) | 4-PYRIDINONETRIAZINE DERIVATIVES AS INHIBITORS OF HIV INTEGRASE | |
| MX355728B (es) | Inhibidores de cinasas. | |
| HK1209277A1 (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors 124--6- | |
| EP3019166A4 (en) | A pharmaceutical combination for the treatment of melanoma | |
| EP2877469A4 (en) | SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS INHIBITORS OF HIV INTEGRASE | |
| IN2014DN07996A (ru) | ||
| MX366983B (es) | Derivados de 1,5-naftiridina e inhibidores de cinasa de cremallallera de leucina embrionica materna que los contienen. | |
| EP3008651A4 (en) | Cross-store licensing for third party products | |
| IN2014DN11078A (ru) | ||
| MX2015008829A (es) | Momelotinib deuterado. | |
| IN2014DN06738A (ru) | ||
| MX2014015345A (es) | Inhibidores piranopiridona de tanquirasa. | |
| MX2018003903A (es) | Compuesto biciclico y uso del mismo para inhibicion de suv39h2. | |
| UA115072C2 (uk) | Похідні гідантоїну | |
| EP3192511A4 (en) | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor | |
| MY165088A (en) | Pharmaceutical compositions comprising alisporivir | |
| NZ717192A (en) | Anti-inflammatory tripeptides | |
| IN2014DN07410A (ru) | ||
| PH12016500809A1 (en) | Glucopyranosyl - substituted indole-urea derivatives and their use as sglt inhibitors | |
| EP3069326A4 (en) | Modular product vending system | |
| MX2015012610A (es) | Pacritinib deuterizado. | |
| EP3016535A4 (en) | Modular impact protection system for athletic wear |